Mirabegron Glenmark (Mirabegron)

Mirabegron works by selectively activating β3‑adrenergic receptors in the detrusor muscle of the bladder. This activation raises cyclic AMP levels, causing smooth‑muscle relaxation, increased bladder capacity, and reduced involuntary contractions that trigger urgency and frequency.

The appropriate dose of mirabegron is determined by the prescribing clinician based on the patient’s medical condition, renal function, and response to therapy. The prescriber will select the starting dose and may adjust it during follow‑up visits to achieve optimal symptom control.

Safety data for mirabegron in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should be avoided unless the potential benefit justifies the potential risk to the fetus or infant, and only under medical supervision.

To order Mirabegron Glenmark, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirabegron belongs to a different therapeutic class than antimuscarinic agents. While antimuscarinics block muscarinic receptors and often cause dry mouth or constipation, mirabegron activates β3‑adrenergic receptors, typically resulting in a lower incidence of anticholinergic side effects but may raise blood pressure in some patients.

Store Mirabegron Glenmark at ambient temperature, preferably below 25 °C. Keep the tablets in the original blister pack, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability throughout its shelf life.

Mirabegron Glenmark is taken orally as a whole tablet, with or without food. Patients should swallow the tablet whole with water and follow the dosing schedule prescribed by their healthcare provider, typically once daily at the same time each day.

The most serious risks include acute urinary retention, severe hypertension, tachycardia, angioedema, anaphylactic reactions, and renal impairment. Patients should be educated to seek immediate medical attention if they experience difficulty urinating, a sudden rise in blood pressure, rapid heartbeat, swelling of the face or throat, or signs of kidney dysfunction.

Mirabegron is contraindicated in patients with uncontrolled hypertension, severe hepatic impairment, significant urinary retention, or known hypersensitivity to mirabegron or any of its excipients. Caution is also advised for individuals with moderate renal impairment or those taking medications that strongly inhibit CYP2D6.